Sequence Information

    • DRAMP ID

    • DRAMP18182

    • Name

    • Sifuvirtide (SFT)

    • Sequence

    • SWETWEREIENYTRQIYRILEESQ EQQDRNERDLLE

    • Description

    • designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformation

    • Activity

    • Anti-HIV

    • Target Organism

      • IC50 of sifuvirtide was 1.2±0.2 nm, compared with 23±6 nm of Enfuvirtide

    • Reference

      • Pharmacokinetics of Sifuvirtide in Treatment-Naive and Treatment-Experienced HIV-Infected Patients.(PMID: 25291974)
      • Recent advances in antiretroviral drugs.(PMID: 20698725)

Clinical Information

    • Medical use

    • HIV fusion inhibitor;AIDS

    • Company

    • Unknown

    • Stage of Development

    • Phase II

    • Comments

    • Phase Ia clinical studies of sifuvirtide (FS0101) in 60 healthy individuals demonstrated good safety, tolerability,and pharmacokinetic profiles. A single-dose regimen (5, 10,20, 30, and 40 mg) by subcutaneous injection once daily at abdominal sites was well tolerated without serious adverse events.

    • Clinical Trials

    • ChiCTR-TNC-08000208
    • ChiCTR-TRC-08000211
    • ChiCTR-TRC-08000238
    • ChiCTR-IPR-15006316